Preclinical Assessment of Nebulized Surfactant Delivered through Neonatal High Flow Nasal Cannula Respiratory Support.
Poractant alfa
aerosol delivery
eFlow Neos
high flow nasal cannula
nebulized surfactant
non-invasive ventilation
respiratory distress syndrome
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
20 May 2022
20 May 2022
Historique:
received:
11
04
2022
revised:
16
05
2022
accepted:
18
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
High-flow nasal cannula (HFNC) is a non-invasive respiratory support (NRS) modality to treat premature infants with respiratory distress syndrome (RDS). The delivery of nebulized surfactant during NRS would represent a truly non-invasive method of surfactant administration and could reduce NRS failure rates. However, the delivery efficiency of nebulized surfactant during HFNC has not been evaluated in vitro or in animal models of respiratory distress. We, therefore, performed first a benchmark study to compare the surfactant lung dose delivered by commercially available neonatal nasal cannulas (NCs) and HFNC circuits commonly used in neonatal intensive care units. Then, the pulmonary effect of nebulized surfactant delivered via HFNC was investigated in spontaneously breathing rabbits with induced respiratory distress. The benchmark study revealed the surfactant lung dose to be relatively low for both types of NCs tested (Westmed NCs 0.5 ± 0.45%; Fisher & Paykel NCs 1.8 ± 1.9% of a nominal dose of 200 mg/kg of
Identifiants
pubmed: 35631679
pii: pharmaceutics14051093
doi: 10.3390/pharmaceutics14051093
pmc: PMC9146271
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Chiesi (Italy)
ID : HFNC
Références
Pediatrics. 2020 Nov;146(5):
pubmed: 33060258
J Korean Med Sci. 2017 Apr;32(4):650-655
pubmed: 28244292
Pediatrics. 2016 Jul;138(1):
pubmed: 27365307
Pharmaceutics. 2020 Apr 02;12(4):
pubmed: 32252349
Arch Dis Child Fetal Neonatal Ed. 2019 May;104(3):F313-F319
pubmed: 30049729
Pediatr Pulmonol. 2019 Aug;54(8):1319-1325
pubmed: 30932345
Neonatology. 2019;115(4):432-450
pubmed: 30974433
Pediatr Pulmonol. 1997 Sep;24(3):222-4
pubmed: 9330420
J Aerosol Med Pulm Drug Deliv. 2013 Dec;26(6):370-9
pubmed: 23421901
J Aerosol Med Pulm Drug Deliv. 2020 Feb;33(1):21-33
pubmed: 31436493
Eur J Pediatr. 2020 Dec;179(12):1909-1911
pubmed: 32710303
Respir Care. 2014 Mar;59(3):443-4
pubmed: 24587482
N Engl J Med. 2016 Sep 22;375(12):1142-51
pubmed: 27653564
Arch Dis Child Fetal Neonatal Ed. 2022 Jul;107(4):386-392
pubmed: 34725105
Gates Open Res. 2019 Mar 14;3:6
pubmed: 31131369
Pediatr Neonatol. 2020 Apr;61(2):174-179
pubmed: 31628028
J Perinatol. 2008 Jan;28(1):42-7
pubmed: 17989697
Pediatr Crit Care Med. 2020 Jul;21(7):e456-e466
pubmed: 32195907
Pediatr Res. 2008 Aug;64(2):141-6
pubmed: 18391845
Arch Dis Child Fetal Neonatal Ed. 2020 Jan;105(1):87-93
pubmed: 31123057
Crit Care Med. 2020 Jun;48(6):e523-e531
pubmed: 32301841
Pediatr Pulmonol. 2015 Nov;50(11):1099-106
pubmed: 25491434
Pediatr Pulmonol. 2020 Feb;55(2):514-520
pubmed: 31833668
J Aerosol Med. 2001 Winter;14(4):433-41
pubmed: 11791684
Respir Care. 2013 Nov;58(11):1840-6
pubmed: 23481441
Pulm Pharmacol Ther. 2021 Feb;66:101986
pubmed: 33338661
Acta Paediatr. 2000 Apr;89(4):460-4
pubmed: 10830460
J Appl Physiol (1985). 1991 Feb;70(2):869-76
pubmed: 2022579
J Aerosol Med Pulm Drug Deliv. 2020 Dec;33(6):314-322
pubmed: 32453638
Respir Res. 2019 Jul 2;20(1):134
pubmed: 31266508
PLoS One. 2017 Jan 6;12(1):e0169190
pubmed: 28060859
Pharmaceutics. 2020 Mar 12;12(3):
pubmed: 32178276
JAMA Pediatr. 2016 Aug 08;:
pubmed: 27532363
BMJ. 2013 Oct 17;347:f5980
pubmed: 24136633
Respir Res. 2021 Feb 26;22(1):71
pubmed: 33637075
Neonatology. 2013;104(1):8-14
pubmed: 23595061
Pediatr Pulmonol. 2017 Mar;52(3):337-344
pubmed: 27392199
PLoS One. 2018 Jul 12;13(7):e0200542
pubmed: 30001410